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lower proportion of females (53.8% vs. 55.7%, respectively; P0.019), and had a
longer mean length of stay (LOS) (13.2 vs. 12.1 days, respectively; P0.001). The
mean cumulative dose was EPO 57,248 Units and DARB 211mcg, resulting in a dose
ratio (Units EPO: mcg DARB) of 271:1. Mean ESA treatment costs were higher for
DARB than for EPO (EPO: $867 vs. DARB: $1,130; P0.001). CONCLUSIONS: In this
analysis of CIA inpatient records, a dose ratio (Units EPO: mcg DARB) of 271:1 was
observed. Mean ESA treatment costs were observed to be approximately 30%
higher for the DARB group than for the EPO group despite a longer LOS for the EPO
group.
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OBJECTIVES: Lung cancer is the leading cause of cancer deaths worldwide (1.38
million cancer deaths, 18.2% of the total) and of cancermorbidity (1.61million new
cases, 12.7% of all new cancers). Currently only three second-line (2L) non-small
cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union,
the chemotherapies pemetrexed and docetaxel as well as the Epidermal Growth
Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) erlotinib. These therapy
alternatives have shown a comparable efficacy (survival benefit). In the past cost
comparisons showed that erlotinib was less costly compared to docetaxel, which
itself was cheaper than pemetrexed. Nowadays erlotinib (and docetaxel) are still
less expensive than pemetrexed; but docetaxel lost patent protection (basic com-
pound patent) at the end of 2010, so the docetaxel drug costs have decreased
rapidly, which poses the question of whether erlotinib still is the least costly ther-
apy alternative in 2L NSCLC. METHODS: Italy has been selected exemplarily to
compare the total therapy costs, estimated by combining country-specific drug
costs, administration costs and adverse event costs of erlotinib and generic do-
cetaxel in 2LNSCLC therapy. Sensitivity analyses on central input parameters have
been performed. RESULTS: The total costs of treating one patient with erlotinib
therapy of €5121 are lower than the docetaxel costs of €6699 for the Italian health-
care setting. Although the drug costs of erlotinib are higher than generic docetaxel
(incremental €3770), the costs of intravenous chemotherapy administration (incre-
mental -€4510) and the costs of adverse event therapy (incremental -€837) lead to
higher total therapy costs of docetaxel compared to the EGFR TKI therapy erlotinib.
CONCLUSIONS: The cost comparison findings for Italy show that erlotinib is still
the less costly therapy alternative in 2L NSCLC. These results were robust to
changes of central input parameters and robust to further potential price decreases
for docetaxel.
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OBJECTIVES: Studies have previously reported specialty-related cost differences
for the treatment of non-melanoma skin cancer (NMSC) but without attempting to
establish a causal relationship. This study addresses if specialty-related cost dif-
ferences in the management of NMSC still persist, controlling for potential
confounders.METHODS:Using a previously validatedmodel for episode of care for
NMSC, patients diagnosed with NMSC were identified in part B of the Medicare
Current Beneficiary Survey claims from 2005-07. Physician specialty exposure dur-
ing an episode was defined in three approximately mutually exclusive categories:
1) General Practitioner/Family Medicine/Internal Medicine/General Surgeon/Oth-
ers; 2) Dermatologist; 3) Otolaryngologist/Plastic Surgeon. A log-linear regression
modelwas built of treatment cost as dependent variable and physician exposure as
independent variable controlling for treatment settings, patient demographics,
health status, treatment procedure, tumor size and tumor location that may con-
tribute to differences in the cost of NMSC management. RESULTS: Over years
2005-2007, 1449 unique episodes of care for the management of NMSC were iden-
tified, 24% of which were not treatment-related episodes. Analyzing treatment-
related episodes only, significantmedian cost differences across the three specialty
categories were observed: $297.4 for generalist/other specialist, $441.5 for derma-
tologist, and $672.8 for otolaryngologist/plastic surgeon. In regression analysis,
compared to dermatologist, having seen a generalist/other specialist was associ-
atedwith 29.6% lower costs (P0.001)while having seen an otolaryngologist/plastic
surgeon was associated with 24.6% higher costs (P0.001). Those living in metro
areas were likely to have 11% (P0.04) higher costs. Treating a tumor in the facial
area was associatedwith 17% (P0.001) higher costs than a tumor in the trunk area
of the body.CONCLUSIONS:This study suggests that controlling for demographics,
health status, and treatment predictors, unaccounted specialty-related cost differ-
ences still exist in the management of NMSC and require further investigation.
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OBJECTIVES: To describe the demographic and clinical characteristics and comor-
bidities of colorectal cancer (CRC) patients and to evaluate the disease-specific
expenditures (i.e., insurer-paid costs and patient-incurred out-of-pocket [OOP] ex-
penses) incurred by CRC patients with one, two, and three ormore lines of therapy.
METHODS: Data were from the Thomson Reuters MarketScan® Research Databases.
The analysis population included patients 18 years with incident CRC during
2005-2009who utilized one ormore lines of CRC therapy (defined by a 90-day gap in
treatment or initiation of a new regimen). Demographic characteristics, health
status indices, and comorbidities were measured at baseline and/or during follow-
up. Expenditure data (i.e., paid amounts of adjudicated claims) were collected for
patients while on therapy. OOP expenses were coinsurance and copayments. Av-
erage per-patient monthly expenditures (2009 US dollars) were calculated in com-
posite for all patients from initiation of first-line therapy through follow-up, and
also disaggregated by each line of therapy. RESULTS: Among 13,670 CRC patients,
9,224 (67.5%) had exactly one line of therapy, 2,836 (20.7%) had exactly two lines,
and 1,610 (11.8%) had three ormore lines of therapy. Total per-patient expenditures
for first-line therapy averaged $12,067 per month, but increased to $13,312 for
patients transitioning to second-line therapy, and to $14,651 for patients transi-
tioning to third-line therapy. Monthly OOP expenses were a small (about 2%) con-
tributor to total costs, ranging from $241, $246, and $238 by respective lines of
therapy. Total monthly expenditures for patients covered by commercial insur-
ance were substantially (50%) higher than for patients covered by Medicare sup-
plemental insurance. CONCLUSIONS: Ranging from about $12,000 to $15,000 per
month by increasing lines of therapy, direct costs of CRC present a significant
economic burden to health plans and self-insured employers. Patient-borne OOP
expenses are relatively small but meaningful contributors to the overall financial
burden imposed by CRC.
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OBJECTIVES: To compare survival and healthcare utilization and costs among
Medicare patients with acute myeloid leukemia (AML) versus a matched cohort of
Medicare patients without cancer.METHODS: Patients aged 65 years in the Sur-
veillance, Epidemiology, and End Results (SEER) cancer registry with a new AML
diagnosis from January 1, 1997 to December 31, 2007 were identified (first diagnosis
termed “index”). Patients were required to have 6 months Medicare Part A and B
benefits pre-index and no managed care enrollment post-index. Patients were ex-
cluded if they had another tumor in SEER pre-index. Medicare patients without
cancer were identified and matched up to 5 to 1 based on age (5 years), gender,
race, geographic location, and common comorbidities. Patientswere followed from
index (or index of the corresponding AML patient among controls) to death or
database end (i.e., December 31, 2007). Study measures included median survival
and health care utilization and costs. Generalized linear models were undertaken
to estimate adjusted costs. RESULTS: A total of 6,888 selected AML patients were
matched to 22,346 controls. Among AML patients and controls respectively, mean
(SD) age was 78.3(7.2) and 72.7(6.7) years, median survival was 2.6 and 131.7
months, mean (SD) total follow-up costs were $90,395($104,228) and $26,900
($41,840), and mean (SD) average monthly follow-up costs were $26,990 ($30,719)
and $269 ($468). The largest proportion of costs was hospitalization-related in both
cohorts (74% and 42% of total, respectively). The cost difference between cohorts
was mainly attributable to hospitalizations ($56,314 difference), followed by out-
patient visits ($3,382 difference) (both p0.001). AML patients and controls had
approximately the same number of emergency department, outpatient hospital,
and home health visits. Regression analyses found AML patients accrued $74,177
more in costs than controls (p0.001). CONCLUSIONS: While AML patients had
shorter median survival, they accrued 3 times more costs, mainly driven by hospi-
talizations. This indicates a substantial economic burden incurred by AML patients
to Medicare.
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OBJECTIVES: To estimate costs associated with adverse events (AEs) in patients
receiving targeted therapies for first-line treatment of metastatic renal cell carci-
noma (mRCC).METHODS:A retrospective study utilizing the IntegratedHealthcare
Information Services (IHCIS) claims data from 2000 to 2009 was conducted. Study
subjects were aged 18 years, had mRCC, and received 1st line treatment with
targeted therapies. AEs of interest comprised abdominal pain, back pain, diarrhea,
dyspnea, extremity pain, fatigue/asthenia, hand-foot syndrome, hypertension,
lymphopenia, nausea/vomiting, neutropenia, and proteinuria. Healthcare encoun-
ters for AEs were based on ICD-9-CM diagnosis/procedure codes on healthcare
claims. Costs of AEs were examined over a 30-day period, beginning with the date
of first mention of each AE, and were estimated based on the difference in total
costs between patients with and without events; nonevented patients similarly
were assigned a “shadow” index date. Direct drug costs of targeted agents were
excluded from the analysis. Multivariate generalized linear models (GLM) with a
log-link function and gamma response probability distribution were utilized to
control for differences in baseline characteristics between patients with and with-
out evidence of adverse events. RESULTS: A total of 533 patients were included in
this analysis: 418 patients with adverse events and 115 patients without adverse
events. Baseline characteristics were generally similar between patients in the two
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